Accelerated development of malaria monoclonal antibodies

Narimane Nekkab; Melissa A Penny

doi:10.1016/j.xcrm.2022.100786

Accelerated development of malaria monoclonal antibodies

Cell Rep Med. 2022 Oct 18;3(10):100786. doi: 10.1016/j.xcrm.2022.100786.

Authors

Narimane Nekkab¹, Melissa A Penny²

Affiliations

¹ Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland.
² Swiss Tropical and Public Health Institute, Allschwil, Switzerland; University of Basel, Basel, Switzerland. Electronic address: melissa.penny@unibas.ch.

Abstract

L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.¹ These promising results are the first of many to usher in a potential new era of malaria prevention.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Adult
Antibodies, Monoclonal* / adverse effects
Antimalarials* / adverse effects
Clinical Trials, Phase I as Topic
Humans
Malaria* / drug therapy

Substances

Antibodies, Monoclonal
Antimalarials